PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933385
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933385
The global IVD (In Vitro Diagnostic) contract manufacturing market was valued at USD 19.66 billion in 2025 and is projected to grow to USD 20.74 billion in 2026, eventually reaching USD 37.23 billion by 2034, exhibiting a CAGR of 7.59% during the forecast period. North America dominated the market in 2025 with a 36.26% share, owing to advanced healthcare infrastructure, high prevalence of chronic diseases, and strong outsourcing trends among medical device companies.
IVD contract manufacturing involves outsourcing the design, development, and production of diagnostic devices to specialized third-party manufacturers. The rising prevalence of chronic conditions such as infectious diseases, diabetes, and cardiovascular disorders has fueled the demand for IVD testing, creating opportunities for contract manufacturers. Moreover, the increasing complexity of diagnostic devices, including multiplex assays, has accelerated the preference for outsourcing production to specialized IVD contract manufacturers such as Thermo Fisher Scientific Inc., Nova Biomedical, and Argonaut Manufacturing Services Inc.
Market Dynamics
Market Drivers
Rising Demand for IVD Diagnostics
The growing disease burden, coupled with awareness campaigns for early detection, is driving the number of diagnostic tests globally. For instance, the International Diabetes Federation reported in 2024 that around 589 million adults live with diabetes worldwide. This increasing diagnostic demand pushes original equipment manufacturers (OEMs) to rely on contract manufacturers for timely and quality production, thereby boosting the IVD contract manufacturing market.
Market Restraints
Intellectual Property (IP) Concerns
Sharing sensitive information, such as assay formulations, reagent compositions, and software codes with contract manufacturers, exposes OEMs to potential IP risks. This concern, coupled with varying IP enforcement across regions, limits outsourcing. According to The HIPAA Journal 2025, 41.2% of third-party data breaches affect healthcare organizations, highlighting the challenges of maintaining confidentiality in contract manufacturing.
Market Opportunities
Expansion in Emerging Economies
Emerging markets like India, Brazil, and Mexico present significant growth potential due to increased healthcare spending, disease screening programs, and governmental initiatives. In 2025, India's Production-Linked Incentive (PLI) scheme encourages domestic manufacturing of diagnostic products, boosting IVD contract manufacturing demand. Additionally, precision diagnostics, personalized medicine, and advancements in microfluidics and molecular diagnostics are creating long-term opportunities for specialized contract manufacturing partnerships.
Market Challenges
Stringent Regulatory Requirements
Distinct regulatory frameworks across geographies and limited review capacities create hurdles for global contract manufacturers. For instance, Europe has only 12 notified bodies under IVDR in 2024, compared to 22 under previous directives, making compliance complex for OEMs and limiting market adoption. High initial investment requirements and dependence on key raw material suppliers also pose challenges for smaller manufacturers.
Market Trends
Technological Advancements in IVD Manufacturing
Integration of automation, robotics, digitization, and AI tools is reshaping contract manufacturing. These technologies enhance precision, reproducibility, scalability, and regulatory compliance. For example, Mayo Clinic 2025 reported that over 50% of pathology cases were digitized and analyzed through digital platforms, indicating a growing adoption of technology in diagnostics. Additionally, point-of-care testing solutions, molecular diagnostics, and collaborative partnerships are reshaping the IVD manufacturing ecosystem.
By Product Type
The market is divided into instruments and consumables. The consumables segment dominated in 2026 with 66.96% share, driven by the increasing number of diagnostic tests globally and product approvals for items such as test cartridges.
By Technology
Segmented into immunodiagnostics, clinical chemistry, molecular diagnostics, hematology, and others, the immunodiagnostics segment dominated in 2025 and is projected to hold 34% share in 2026, due to rising prevalence of chronic and infectious diseases. Molecular diagnostics is projected to grow at a CAGR of 7.4%.
By Service Type
The manufacturing services segment led the market with 71.98% share in 2026, attributed to growing demand for chronic disease diagnostics and the establishment of new facilities, such as SCIENION's ISO5 cleanrooms in 2022. Assay development services are expected to grow at 7.5% CAGR.
By End User
Medical device companies dominated in 2025, with a projected 60.22% share in 2026, due to increased test volumes and the growing number of medical device companies. Pharmaceutical and biotechnology companies are expected to grow at a CAGR of 7.5%.
North America led the market in 2025 at USD 7.13 billion, and is projected at USD 7.55 billion in 2026, with the U.S. estimated at USD 6.42 billion. Europe reached USD 6.16 billion in 2025, with the U.K., Germany, and France holding USD 1.04 billion, 1.41 billion, and 1.18 billion in 2026, respectively. Asia Pacific was valued at USD 4.11 billion in 2025, with India and China at USD 0.66 billion and 1.43 billion in 2026. Latin America reached USD 1.50 billion in 2025, while GCC in the Middle East & Africa reached USD 0.42 billion in 2025.
Competitive Landscape
Key players include Thermo Fisher Scientific Inc., Argonaut Manufacturing Services Inc., IVD Technologies, Bio-Techne, Invetech, Merck KGaA, Fujirebio, and Celestica Inc. These companies focus on strategic collaborations, facility expansions, and product portfolio enhancements to maintain market dominance. Notable developments include Argonaut Manufacturing Services collaborating with Akoya Biosciences in January 2025, and T&D Diagnostics partnering with Genenest in April 2025 to expand manufacturing in India.
Conclusion
The global IVD contract manufacturing market is poised to grow from USD 20.74 billion in 2026 to USD 37.23 billion by 2034, driven by rising chronic disease prevalence, increasing demand for diagnostic tests, technological integration, and strategic partnerships. North America continues to dominate, while emerging markets in Asia Pacific and Latin America offer lucrative growth opportunities. Despite regulatory complexities and IP concerns, advancements in automation, molecular diagnostics, and point-of-care testing are expected to sustain the market's growth trajectory through 2034.
Segmentation By Product Type, Technology, Service Type, End User, and Region
By Product Type * Instruments
By Technology * Immunodiagnostics
By Service Type * Manufacturing Services
By End User * Medical Device Companies
By Region * North America (By Product Type, By Technology, By Service Type, By End User, and by Country)